Kesimpta (Ofatumumab)

Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 antigen on mature B cells. The binding activates complement‑dependent cytotoxicity and antibody‑dependent cellular cytotoxicity, leading to rapid depletion of CD20‑positive B cells and modulation of the autoimmune response that drives multiple sclerosis.

The dosage regimen for Kesimpta is determined by the prescribing clinician based on the approved label and individual patient factors. Healthcare professionals set the dose, frequency, and any titration steps, and patients should follow the prescriber’s instructions without deviation.

Data on the use of Kesimpta in pregnancy and lactation are limited. The product is generally not recommended for pregnant or nursing women unless the potential benefit justifies the potential risk. Physicians should discuss possible risks and alternatives with patients who are or may become pregnant.

To order Kesimpta, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details—including cold‑chain handling where required—and assists with import documentation.

The primary alternative in the anti‑CD20 class is ocrelizumab, another monoclonal antibody that depletes CD20‑positive B cells. Both agents share a similar mechanism, but they differ in dosing frequency, administration route (intravenous for ocrelizumab versus subcutaneous for Kesimpta), and specific safety profiles. Choice of therapy depends on clinical judgment, patient preference, and individual risk considerations.

Kesimpta must be stored refrigerated at 2 °C to 8 °C. It should be kept in its original packaging to protect from light, and it must never be frozen or shaken. If temporary temperature excursions occur, the product should be inspected for visual changes before use.

Kesimpta is supplied as a 20 mg/mL solution for subcutaneous injection. The injection is typically performed by a healthcare professional or, after appropriate training, by the patient themselves using the pre‑filled device provided in the kit. The injection site is usually the abdomen or thigh, and rotating sites is recommended.

The most serious adverse events include progressive multifocal leukoencephalopathy (PML), severe or opportunistic infections, and reactivation of hepatitis B infection. Patients should be monitored closely for signs of infection, and hepatitis B screening is required before initiating therapy.

Kesimpta is contraindicated in individuals with known hypersensitivity to ofatumumab or any of the excipients, active severe infections, and in patients with active hepatitis B infection. Caution is also advised for those with compromised immune systems or a history of PML.